More from the company
Published: 2015-11-06 13:04:06
The interim report can also be found on WntResearch homepage: www.wntresearch.com
For additional information please contact:
Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708
About WntResearch
WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.